SciSparc Ltd. (Nasdaq: SPRC) ('Company” or 'SciSparc”), a company engaged in clinical-stage pharmaceutical developments ...

Adults prescribed a GLP-1 agent had a 12% higher risk for developing a new chronic cough -- one that persists for over 8 ...

Subscribers to our WhatsApp lines sent us a link to a Facebook post claiming that fig leaves can help with different health ...

Leading data was presented on the excellent 5-year outcomes of the RefluxStop® device, highlighting its long-term effectiveness in treating gastroesophageal reflux disease (GERD). Published data from ...

The U.S. Food and Drug Administration has approved reformulated ranitidine tablets, marking the return of this important acid ...

Surgical Gastroenterologist Dr Anshuman Kaushal from Apollo Hospital has warned that persistent acidity and heartburn may actually indicate Gastroesophageal Reflux Disease (GERD), a serious condition ...

SciSparc shares are surging after it moved to acquire MUSE endoscopy IP, broadening beyond neuroscience into GERD device ...

Cinclus Pharma Holding AB is hosting a virtual event featuring Professor Prateek Sharma to discuss the treatment landscape and unmet medical needs for erosive GERD patients, highlighting their drug ...

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) is one of the best upside stocks to buy now. On November 6, BioCryst ...

The acquisition positions SciSparc to enter the growing GERD device market, which according to MarkNtel Advisors is valued at approximately $2.5 billion in 2024 and projected to reach $3.03 billion by ...

SciSparc Ltd. (NASDAQ:SPRC) jumped 26.8% in premarket trading on Wednesday after the clinical-stage pharmaceutical firm ...

USA: A new multicenter US cohort study has identified a potential link between the use of glucagon-like peptide-1 receptor ...